Kymera Therapeutics, Inc.·4

Dec 17, 6:07 PM ET

Mainolfi Nello 4

4 · Kymera Therapeutics, Inc. · Filed Dec 17, 2025

Insider Transaction Report

Form 4
Period: 2025-12-17
Mainolfi Nello
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-17$38.53/sh+2,595$99,985663,077 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-172,595272,505 total
    Exercise: $38.53Exp: 2032-03-01Common Stock (2,595 underlying)
Footnotes (1)
  • [F1]The shares underlying this stock option are fully vested and exercisable.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4